Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
XENE
XENE
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
XENE News
Xenon Pharmaceuticals Grants 42,300 Stock Options to New Employees
Jan 16 2026
Globenewswire
Biohaven's BHV-7000 Fails Phase 2 Depression Trial, Shares Drop 15.45%
Dec 26 2025
Benzinga
Significant Monday Options Trading: MDB, XENE, SNOW
Dec 08 2025
NASDAQ.COM
Xenon Pharmaceuticals Reports 90.9% Monthly Seizure Frequency Reduction in Long-Term Azetukalner Study
Dec 05 2025
Globenewswire
Xenon Reports 90.9% Seizure Frequency Reduction in Long-Term Epilepsy Study
Dec 05 2025
Newsfilter
Xenon Pharmaceuticals Grants 39,250 Stock Options to New Employees
Dec 04 2025
Globenewswire
Xenon Pharmaceuticals Grants 39,250 Stock Options to New Employees
Dec 04 2025
Newsfilter
JP Morgan Keeps Overweight Rating on Xenon Pharmaceuticals and Increases Price Target to $60
Nov 18 2025
Benzinga
RBC Capital Reaffirms Outperform Rating for Xenon Pharmaceuticals and Increases Price Target to $58
Nov 04 2025
Benzinga
Needham Affirms Buy Rating on Xenon Pharmaceuticals, Keeps $55 Price Target Intact
Nov 04 2025
Benzinga
Xenon Scheduled to Release Q3 2025 Financial Results on November 3, 2025
Oct 27 2025
Newsfilter
Chardan Capital Reaffirms Buy Rating on Xenon Pharmaceuticals with $55 Price Target Intact
Oct 07 2025
Benzinga
Options Trading for Xenon Pharmaceuticals (XENE) in the First Week of November 21st
Sep 22 2025
NASDAQ.COM
Design Therapeutics Names Justin Gover to Board of Directors
Sep 10 2025
Globenewswire
RBC Capital Affirms Outperform Rating for Xenon Pharmaceuticals, Keeps $55 Price Target Intact
Sep 02 2025
Benzinga
Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target
Aug 12 2025
Benzinga
Show More News
